secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001104659-24-085826
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed
--------------------------------------------------------------------------------

- Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.
- Viatris collaboration revenue $14.3M, up 4% YoY; implied 35% share of YUPELRI net sales $19.1M (down 1%).
- YUPELRI net sales (Viatris) $54.5M, down 1%; demand up 13% and hospital share hit all-time highs.
- CYPRESS study: last patient enrollment now expected mid-2025; top-line data ~6 months later.
- TRELEGY Q2 global net sales ~$1.1B (+40% YoY); up to $50M milestones achievable in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924085826/0001104659-24-085826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924085826/tm2420794d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-085826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer